5-(tert-butyl-dimethyl-silanyloxymethyl)-2-methyl-phenylamine | 309712-97-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(tert-butyl-dimethyl-silanyloxymethyl)-2-methyl-phenylamine
• 英文别名: 5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-methylaniline；5-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-methylaniline
• CAS: 309712-97-8
• 化学式: C₁₄H₂₅NOSi
• 分子量: 251.444
• InChiKey: MLVDSEVPTRLEPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(tert-butyl-dimethyl-silanyloxymethyl)-2-methyl-phenylamine 在 盐酸 、 重铬酸吡啶 、 叔丁基锂 、 N,N,N-trimethylbenzenemethanaminium dichloroiodate 、 三乙胺 、 calcium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 生成 2-[5-((R)-Hydroxy-{(R)-4-[(E)-(S)-2-methoxymethyl-pyrrolidin-1-ylimino]-2,2,6,6-tetramethyl-tetrahydro-pyran-3-yl}-methyl)-4-iodo-2-methyl-phenyl]-isoindole-1,3-dione
  参考文献：
  名称：

  Nodulisporic Acid A Synthetic Studies. 1. Overall Strategy and Construction of a Western Hemisphere Subtarget

  摘要：

  [GRAPHICS]In this, the first of two Letters, we outline our overall strategy for the construction of (+)-nodulisporic acid A (1), a representative member of a new class of indole diterpenes. In addition, we describe the efficient assembly of (-)-6, an advanced western hemisphere subtarget, comprising the ABC rings of (+)-nodulisporic acid A (1). The synthesis proceeded in 9% overall yield (longest linear sequence, 11 steps), exploiting a Shibasaki-Mori tandem transmetalation-cyclization to construct ring B.

  DOI：

  10.1021/ol0168871
• 作为产物：
  描述：

  3-氨基-4-甲基苯甲醇 生成 5-(tert-butyl-dimethyl-silanyloxymethyl)-2-methyl-phenylamine
  参考文献：
  名称：

  Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions

  摘要：

  该发明提供了一般式中的取代苯基化合物，其中R1、T、U和Ar如规范中定义，其制备方法，含有它们的药物组合物，制备药物组合物的方法，以及它们在治疗中的用途。

  公开号：

  US06555541B1

文献信息

• [EN] INHIBITORS OF JANUS KINASES<br/>[FR] INHIBITEURS DE JANUS KINASES
  申请人：MERCK & CO INC

  公开号：WO2009035575A1

  公开（公告）日：2009-03-19

  The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

  这项即时发明提供了抑制四种已知哺乳动物JAK激酶（JAK1、JAK2、JAK3和TYK2）和PDK1的化合物。该发明还提供了包含这种抑制性化合物的组合物以及通过向需要治疗骨髓增生性疾病或癌症患者施用该化合物来抑制JAK1、JAK2、JAK3、TYK2和PDK1活性的方法。
• Indole Diterpene Synthetic Studies. Total Synthesis of (+)-Nodulisporic Acid F and Construction of the Heptacyclic Cores of (+)-Nodulisporic Acids A and B and (−)-Nodulisporic Acid D
  作者：Amos B. Smith、Akin H. Davulcu、Young Shin Cho、Kazuyuki Ohmoto、László Kürti、Haruaki Ishiyama

  DOI：10.1021/jo062422i

  日期：2007.6.1

  eastern and western hemisphere subtargets via the indole synthesis protocol developed in our laboratory. Subsequent elaboration of rings E and F, however, revealed the considerable acid instability of the C(24) hydroxyl, thereby preventing further advancement. Nonetheless, preparation of the heptacyclic core of (+)-nodulisporic acids A and B, the total synthesis of (+)-nodulisporic acid F, the simplest member

  描述了构建（+）-去甲孢酸A（1）和B（2）的第一代策略。该策略需要通过我们实验室开发的吲哚合成方案将东半球和西半球的子目标联合起来。然而，随后对环E和F的修饰揭示了C（24）羟基的明显酸不稳定性，从而阻止了进一步的发展。然而，制备（+）-瘤孢子酸A和B的七环核，（+）-瘤孢子酸F的全合成，瘤孢子酸家族的最简单成员，以及（-）-的七环核的精细化获得了根瘤菌酸D。
• INHIBITORS OF JANUS KINASES
  申请人：Siu Tony

  公开号：US20100197634A1

  公开（公告）日：2010-08-05

  The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

  本发明提供了一种抑制四种已知哺乳动物JAK激酶（JAK1、JAK2、JAK3和TYK2）和PDK1的化合物。本发明还提供了包含这种抑制剂化合物的组合物以及通过向需要治疗骨髓增生性疾病或癌症的患者投药来抑制JAK1、JAK2、JAK3、TYK2和PDK1活性的方法。
• Inhibitors of janus kinases
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08349865B2

  公开（公告）日：2013-01-08

  The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

  本发明提供了抑制四种已知哺乳动物JAK激酶（JAK1、JAK2、JAK3和TYK2）以及PDK1的化合物。本发明还提供了包含这种抑制剂化合物的组合物以及通过向需要治疗骨髓增生性疾病或癌症患者施用该化合物来抑制JAK1、JAK2、JAK3、TYK2和PDK1活性的方法。
• Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions
  申请人：Astrazeneca UK Limited

  公开号：US06555541B1

  公开（公告）日：2003-04-29

  The invention provides substituted phenyl compounds of general formula wherein R1, T, U and Ar are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.

  该发明提供了一般式中的取代苯基化合物，其中R1、T、U和Ar如规范中定义，其制备方法，含有它们的药物组合物，制备药物组合物的方法，以及它们在治疗中的用途。